- Home
- GMRE vs RGNX Comparison
GMRE vs RGNX Comparison
Compare GMRE & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMRE
- RGNX
- Stock Information
- Founded
- GMRE 2011
- RGNX 2008
- Country
- GMRE United States
- RGNX United States
- Employees
- GMRE N/A
- RGNX N/A
- Industry
- GMRE Real Estate Investment Trusts
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GMRE Real Estate
- RGNX Health Care
- Exchange
- GMRE Nasdaq
- RGNX Nasdaq
- Market Cap
- GMRE 508.9M
- RGNX 451.1M
- IPO Year
- GMRE N/A
- RGNX 2015
- Fundamental
- Price
- GMRE $7.60
- RGNX $9.03
- Analyst Decision
- GMRE Buy
- RGNX Strong Buy
- Analyst Count
- GMRE 3
- RGNX 8
- Target Price
- GMRE $10.38
- RGNX $28.50
- AVG Volume (30 Days)
- GMRE 619.5K
- RGNX 502.6K
- Earning Date
- GMRE 11-05-2025
- RGNX 11-05-2025
- Dividend Yield
- GMRE 7.91%
- RGNX N/A
- EPS Growth
- GMRE N/A
- RGNX N/A
- EPS
- GMRE 0.07
- RGNX N/A
- Revenue
- GMRE $141,896,000.00
- RGNX $155,782,000.00
- Revenue This Year
- GMRE $7.69
- RGNX $203.27
- Revenue Next Year
- GMRE $4.04
- RGNX $0.58
- P/E Ratio
- GMRE $113.04
- RGNX N/A
- Revenue Growth
- GMRE 2.95
- RGNX 74.95
- 52 Week Low
- GMRE $6.06
- RGNX $5.04
- 52 Week High
- GMRE $10.46
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- GMRE 61.41
- RGNX 49.37
- Support Level
- GMRE $7.60
- RGNX $8.82
- Resistance Level
- GMRE $7.64
- RGNX $10.08
- Average True Range (ATR)
- GMRE 0.15
- RGNX 0.54
- MACD
- GMRE -0.00
- RGNX -0.05
- Stochastic Oscillator
- GMRE 56.78
- RGNX 25.27
About GMRE Global Medical REIT Inc.
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.